Gilead operates a high-quality franchise with 43% return on equity, best-in-class margins of 31%, and a perfect four-quarter earnings beat streak, while 14.1% upside to the analyst consensus target and a 2.4-to-1 risk/reward offer a structurally sound setup. The near-term constraint is price momentum: the stock is below its 200-day moving average in what the data characterizes as a pullback within a still-rising trend—not a confirmed breakdown—but momentum has not yet turned to support a new commitment, and 90% of revenue concentrated in three wholesale distributors is a latent vulnerability.
Thesis pillars
- High Quality Franchise Best In Class Margins→Stable
- Consistent Earnings Delivery→Stable
- Momentum Headwind Not Confirmed Breakdown→Stable
- +1 more pillar — see the Why tab for full reasoning
Gilead Sciences, Inc. (GILD) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - General
Wait for pullback to $128.97. At $130.95 the A.R:R is 1.0:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $128.97 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: three large wholesalers (Cardinal Health, Cencora, McKesson) (90.0%); Thin upside margin: 8.1%.
Gilead Sciences develops antiviral and oncology medicines across HIV, hepatitis, COVID-19, and cancer in more than 35 countries, with more than 25 approved therapies in 2025. U.S. products are distributed primarily through three wholesalers—Cardinal Health, Cencora, and... Read more
Wait for pullback to $128.97. At $130.95 the A.R:R is 1.0:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $128.97 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: three large wholesalers (Cardinal Health, Cencora, McKesson) (90.0%); Thin upside margin: 8.1%. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 6.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: conservative.
About Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Biktarvy, a once-daily single-tablet HIV regimen combining bictegravir, emtricitabine, and tenofovir alafenamide, holds U.S. patent protection through 2036 following settlement agreements signed in October 2025 with Lupin, Cipla, and Laurus Labs that preclude generic entry before April 1, 2036. Gilead Sciences' 2025 commercial portfolio exceeded 25 approved therapies spanning HIV, hepatitis B and C, oncology, and COVID-19, marketed across more than 35 countries. FDA also approved Yeztugo in 2025 as the first twice-yearly HIV PrEP capsid inhibitor available in the United States.
Gilead Sciences distributes products in the U.S. exclusively through the wholesale channel, with Cardinal Health, Cencora, and McKesson historically accounting for approximately 90% of U.S. gross product sales; for most HIV products the company uses multiple contract manufacturing organizations to maintain primary and back-up supply. HIV products represent a substantial portion of total revenue, and the company faces patent expirations across its portfolio — Trodelvy's U.S. compound patent expires in 2028 (regulatory exclusivity in 2032), and Tecartus' U.S. patent expires in 2027. Gilead also earns royalties and collaboration payments from arrangements with Merck, Arcellx, and Arcus Biosciences for pipeline programs including anitocabtagene autoleucel (in FDA review for multiple myeloma) and domvanalimab plus zimberelimab in Phase 3 for NSCLC.
Show full overview
In January 2026, the Department of Health and Human Services selected Biktarvy for Medicare price negotiation under the Inflation Reduction Act, with negotiated prices to take effect beginning in 2028. In December 2025, Gilead reached an agreement with the current U.S. Presidential administration to pause Section 232 tariffs for three years and implement most-favored-nation prices in Medicaid for select existing and future launched products. The 10-K notes that the full impact of these pricing mechanisms on revenue and Medicaid rebate obligations remains uncertain.
See also: Healthcare · Drug Manufacturers - General
From Gilead Sciences, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-07-06Recent Developments — Gilead Sciences, Inc.
Latest news
- NEWS Gilead Sciences (NASDAQ:GILD) CEO Sells $1,291,600.00 in Stock - MarketBeat — MarketBeat negative
- NEWS Gilead (NASDAQ: GILD) CEO sells 10,000 shares in planned trade - Stock Titan — Stock Titan negative
- NEWS Assessing Whether Gilead Sciences (GILD) Looks Undervalued After Recent Share Price Performance - simplywall.st — simplywall.st positive
- NEWS Morgan Stanley Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat — MarketBeat positive
- NEWS GILD Upgraded by Maxim Group -- Price Target Announced at $165 - GuruFocus — GuruFocus positive
Generated 2026-07-06T05:40:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerthree large wholesalers (Cardinal Health, Cencora, McKesson)90%10-K Item 1: 'approximately 90% of our gross product sales in the U.S. have been to three large wholesalers—Cardinal Health, Inc., Cencora, Inc. and McKesson Corporation'
- MEDIUMProductHIV products10-K Item 1A: 'We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $128.97. At $130.95 the A.R:R is 1.0:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $128.97 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: three large wholesalers (Cardinal Health, Cencora, McKesson) (90.0%); Thin upside margin: 8.1%. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $141.90 (+8.4%), stop $122.33 (−7.0%), A.R:R 1.0:1. Score 6.5/10, moderate confidence.
Take-profit target: $141.90 (+10.0% upside). Target $141.90 (+8.4%), stop $122.33 (−7.0%), A.R:R 1.0:1. Stop-loss: $122.33.
Concentration risk — Customer: three large wholesalers (Cardinal Health, Cencora, McKesson) (90.0%); Thin upside margin: 8.1%.
Gilead Sciences, Inc. trades at a P/E of 17.9 (forward 13.6). TrendMatrix value score: 6.2/10. Verdict: Buy (Wait for Entry).
39 analysts cover GILD with a consensus score of 4.1/5. Average price target: $158.
What does Gilead Sciences, Inc. do?Gilead Sciences develops antiviral and oncology medicines across HIV, hepatitis, COVID-19, and cancer in more than 35...
Gilead Sciences develops antiviral and oncology medicines across HIV, hepatitis, COVID-19, and cancer in more than 35 countries, with more than 25 approved therapies in 2025. U.S. products are distributed primarily through three wholesalers—Cardinal Health, Cencora, and McKesson—representing approximately 90% of U.S. gross product sales. HIV accounts for a substantial portion of total revenue; Biktarvy holds U.S. patent protection through 2036.